The race is on for new weight loss medications based on GLP-1s to hit the market
S., Hohm A., Vandergrift L
A recent meta-analysis, which analysed data from the EMPA-REG OUTCOME trial and the VERTS CV study, suggested that the administration of empagliflozin/ertugliflozin significantly reduced the risk of developing new-onset OSA by 47% ( p = 0.003) [103]
In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]
Check the certification of the compounding pharmacies, as some pharmacies have certification from Good Manufacturing Practice (GMP) Monitoring and adjustment It is essential to monitor your progress while Ozempic microdosing, such as tracking weight loss, HbA1C, and potential side effects
La revisin concluye que, pese a los notables beneficios metablicos y cardiovasculares indirectos de estos frmacos, no se ha comprobado un impacto positivo en la capacidad cardiorrespiratoria , elemento clave de la salud a largo plazo
